Navigation Links
Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
Date:8/29/2012

JACKSONVILLE, Fla. Removing the entire pancreas in patients with cancer or precancerous cysts in part of the organ does not result in unmanageable diabetes as many physicians previously believed, research at Mayo Clinic in Florida has found. The study, published online Sunday in the journal HPB Surgery, evaluates how well patients who had their entire pancreas removed could control their resulting diabetes. The pancreas produces insulin to remove sugar from the blood, so when the organ is gone, insulin must be replaced, usually through an external pump or with injections.

The researchers examined control of insulin over several years in 14 patients whose entire pancreas was removed. They compared their findings with 100 people with type 1 diabetes, and must use insulin replacement. They found both groups had little difficulty controlling their blood sugar, and no complications resulted.

The findings should reassure physicians and surgeons that removing the entire pancreas is reasonably safe and effective, says senior investigator Michael B. Wallace, M.D., chair of the Division of Gastroenterology & Hepatology at Mayo Clinic in Florida.

"What has confounded surgery for pancreatic cancers and precancerous cysts for a long time is the notion that if the entire organ is removed, patients will have great difficulty in controlling the resulting diabetes," Dr. Wallace says. "Most surgeons try to leave as much of the pancreas as possible".

"What we have shown here is that, due to wonderful recent improvements in insulin therapy, patients without a pancreas can control their blood sugar as effectively as type 1 diabetes patients can," he says.

Although this study was small, Dr. Wallace says the findings are mirrored in the experiences of patients treated at Mayo Clinic in Florida with total pancreas removal.

Even though the approach of preserving as much of the pancreas as possible benefits most patients, leaving part of the pancreas in some patients may put them at risk of developing hard-to-detect cancer in the remaining organ, he says.

Similarly, patients who have a potentially precancerous cystic condition known as intraductal papillary mucinous neoplasm in part of the pancreas can develop the same cysts in the part of the pancreas that remains after partial removal, he says. Removing the entire pancreas eliminates the possibility of recurrence in the residual pancreas.

"Most surgeons today make difficult decisions about how much of the pancreas to remove in a patient, but that process may become a little more straightforward now that we have demonstrated patients do well when their entire pancreas is removed," Dr. Wallace says.


'/>"/>
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
2. Mayo Clinic: Common blood pressure drug linked to severe GI problems
3. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
4. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
5. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
6. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
7. Confusion Over Diabetes Types Adds to Patients Woes
8. Psoriasis patients at high risk of diabetes
9. Radiation for Childhood Cancer Might Raise Diabetes Risk
10. Circadian clock research may enable designer plants, and cancer and diabetes treatments
11. Sensor detects glucose in saliva and tears for diabetes testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:12/6/2016)... Georgia (PRWEB) , ... December 06, 2016 , ... ... consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry leading ... This prestigious, annual award recognizes USA as among the global elite in employer-sponsored ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, ... today on its R&D program in the use ... pulmonary disease (COPD). In June, 2015 InMed initiated ... to identify the targets and potential active compounds ... COPD. Subsequently, with in vitro assays using human ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
(Date:12/5/2016)... 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... presentation of preclinical and manufacturing data that support SB-525, its ... Annual Meeting of the American Society of Hematology (ASH) ... from December 3-6, 2016. "We have developed an ... we believe is highly competitive, and we remain on track ...
Breaking Medicine Technology: